Format

Send to

Choose Destination
Ther Clin Risk Manag. 2019 Jun 17;15:765-772. doi: 10.2147/TCRM.S188761. eCollection 2019.

Use of levosimendan in acute and advanced heart failure: short review on available real-world data.

Author information

1
Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY 10595, USA.

Abstract

Published data have shown potential advantages of levosimendan in the management of acute decompensated heart failure and advanced heart failure when standard medical therapies threaten hemodynamics and organ perfusion are unable to alleviate clinical symptoms. Levosimendan distinguishes itself from other catecholaminergic inotropes by its three mechanisms of action: positive inotropy, vasodilation, and cardioprotection. In addition, its pharmacokinetics allow for a longer duration of action from the metabolite OR1896 allowing for further cardiovascular therapeutic effects for several days, even after discontinuation of the parent drug.

KEYWORDS:

heart failure; inotropic therapy; levosimendan

Conflict of interest statement

The authors report no conflicts of interest in this work.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center